Treats active duodenal ulcer. ANDA 207476, held by ScieGen Pharmaceuticals. Omeprazole; Sodium Bicarbonate.
As of Nov 21, 2026, ANDA 207476 (Omeprazole and Sodium Bicarbonate), held by ScieGen Pharmaceuticals, was first approved by FDA on Dec 6, 2016, with 4 approved supplements and 0 published complete response letters.
Omeprazole and sodium bicarbonate is a proton pump inhibitor (PPI) indicated for:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 6, 2016 | Original application | Approved | None posted |
| Omeprazole and Sodium Bicarbonate20MG;1.1GM · capsule;oral | Omeprazole; Sodium Bicarbonate | Rx |
| Omeprazole and Sodium Bicarbonate40MG;1.1GM · capsule;oral | Omeprazole; Sodium Bicarbonate | Rx |
| Jan 11, 2024 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jan 11, 2024 | Supplement 12Labeling · Standard review | Approved | None posted |
| Feb 24, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Feb 24, 2020 | Supplement 5Labeling · Standard review | Approved | None posted |
| Dec 6, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters